Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.

[1]  R. Wolf,et al.  Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. , 2016, Bioorganic & medicinal chemistry letters.

[2]  J. Chandrasekhar,et al.  Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability. , 2016, Journal of medicinal chemistry.

[3]  San-qi Zhang,et al.  Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[4]  J. McCarter,et al.  Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quino , 2016, Journal of medicinal chemistry.

[5]  J. Chandrasekhar,et al.  2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors. , 2016, Journal of medicinal chemistry.

[6]  Xiaodong Ma,et al.  Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. , 2016, Journal of medicinal chemistry.

[7]  San-qi Zhang,et al.  Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. , 2015, Bioorganic & medicinal chemistry.

[8]  Jian Ding,et al.  Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond , 2015, Medicinal research reviews.

[9]  A. Markham.  Idelalisib: First Global Approval , 2014, Drugs.

[10]  Feng Tang,et al.  The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[11]  M. Davids,et al.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.

[12]  P. Norman.  Selective PI3Kδ inhibitors, a review of the patent literature , 2011, Expert opinion on therapeutic patents.

[13]  E. Hirsch,et al.  Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. , 2011, Current medicinal chemistry.